LOS ANGELES, Sept. 8, 2004 (PRIMEZONE) -- HeartSTAT Technology, Inc. (Pink Sheets:HSTA) today announced that Mr. Arthur A. Alfaro was recently formally elected as a member of the Board of Directors.
Arthur A. Alfaro has been President, CEO and co-founder of ORTHOCON, a privately held orthobiologics company since early 2004. Previously, Mr. Alfaro was President, Chief Operating Officer and Director of Osteotech, Inc., a publicly traded orthobiologics medical device company; president of Sofamor Danek Thoracolumbar, a spinal medical device division of Medtronic Corporation; vice president and general manager at Carbomedics, Inc., a heart valve division of Sulzer Cardiovascular A. G. Mr. Alfaro also served as Vice President and General Manager at Boston Scientific Corporation and has held various positions in sales, marketing and international with Ethicon, a Johnson & Johnson Company. He received a BA degree from University of Maryland and an MBA from Fairleigh Dickinson University.
Commenting on the announcement, Ted Russell, Chairman and Chief Executive Officer of HeartSTAT stated, "Arthur Alfaro is a highly experienced manager of large successful medical companies, having specific experience in general operational management, product market strategy and market requirements. He has already contributed to our business start up and brings executive management perspective to our Board. We welcome him to the Board and are confident that he can add significant value to our goal to achieve market leadership in patient monitoring and cardiovascular disease management."
About HeartSTAT Technology, Inc.
HeartSTAT is bringing to market the first practical system for monitoring blood flow perfusion (blood oxygen transport) and heart dynamics, which have been impracticalities until now.
Initially, the new HeartSTAT technology is intended for early interventional prevention of septic shock and other conditions that kill 300,000 patients in U.S. hospitals annually, a mortality that is almost as large as cancer. The system is for revealing vital patient problems that alter blood flow while BP does not change, to enable providing earlier and more specific intervention than is presently possible. This system can also provide real time monitoring of heart loads and cardiovascular biophysics, which may later open up a large internet-based physician market for managing cardiovascular disease, drug interaction, heart attacks and heart failure.
More information is available at www.HeartSTAT.com.
Statements in this release are made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties including, without limitation, continued acceptance of the Company's services, increased levels of competition for the Company and dependence on the performance of the Management of the Company.